NATCO Pharma Limited

NSEI:NATCOPHARM Stock Report

Market Cap: ₹250.3b

NATCO Pharma Valuation

Is NATCOPHARM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NATCOPHARM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NATCOPHARM (₹1397.35) is trading above our estimate of fair value (₹1006.05)

Significantly Below Fair Value: NATCOPHARM is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NATCOPHARM?

Key metric: As NATCOPHARM is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NATCOPHARM. This is calculated by dividing NATCOPHARM's market cap by their current earnings.
What is NATCOPHARM's PE Ratio?
PE Ratio12.9x
Earnings₹19.45b
Market Cap₹250.28b

Price to Earnings Ratio vs Peers

How does NATCOPHARM's PE Ratio compare to its peers?

The above table shows the PE ratio for NATCOPHARM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average51.9x
506943 J. B. Chemicals & Pharmaceuticals
47.4x19.4%₹289.8b
ERIS Eris Lifesciences
54.1x30.7%₹188.4b
524558 Neuland Laboratories
63.4x33.9%₹177.4b
GLAND Gland Pharma
42.5x25.8%₹294.0b
NATCOPHARM NATCO Pharma
12.9x-20.1%₹250.3b

Price-To-Earnings vs Peers: NATCOPHARM is good value based on its Price-To-Earnings Ratio (12.9x) compared to the peer average (51.9x).

Price to Earnings Ratio vs Industry

How does NATCOPHARM's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.7xn/aUS$73.57m
524652 Ind-Swift
3.1xn/aUS$19.84m
No more companies available in this PE range
NATCOPHARM 12.9xIndustry Avg. 35.3xNo. of Companies19PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: NATCOPHARM is good value based on its Price-To-Earnings Ratio (12.9x) compared to the Indian Pharmaceuticals industry average (35.3x).

Price to Earnings Ratio vs Fair Ratio

What is NATCOPHARM's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NATCOPHARM PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.9x
Fair PE Ratio22.2x

Price-To-Earnings vs Fair Ratio: NATCOPHARM is good value based on its Price-To-Earnings Ratio (12.9x) compared to the estimated Fair Price-To-Earnings Ratio (22.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NATCOPHARM forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,397.35
₹1,337.27
-4.3%
23.7%₹1,675.00₹690.00n/a11
Dec ’25₹1,375.50
₹1,343.09
-2.4%
23.9%₹1,675.00₹690.00n/a11
Nov ’25₹1,426.90
₹1,348.73
-5.5%
24.0%₹1,675.00₹690.00n/a11
Oct ’25₹1,400.30
₹1,283.27
-8.4%
24.0%₹1,625.00₹690.00n/a11
Sep ’25₹1,537.55
₹1,249.25
-18.8%
25.3%₹1,625.00₹690.00n/a12
Aug ’25₹1,362.00
₹1,063.75
-21.9%
18.7%₹1,250.00₹620.00n/a12
Jul ’25₹1,198.95
₹1,063.75
-11.3%
18.7%₹1,250.00₹620.00n/a12
Jun ’25₹997.65
₹1,063.75
+6.6%
18.7%₹1,250.00₹620.00n/a12
May ’25₹1,018.15
₹975.36
-4.2%
18.2%₹1,200.00₹620.00n/a11
Apr ’25₹973.70
₹930.82
-4.4%
19.0%₹1,125.00₹620.00n/a11
Mar ’25₹982.75
₹912.30
-7.2%
19.2%₹1,125.00₹620.00n/a10
Feb ’25₹869.30
₹822.45
-5.4%
18.8%₹1,125.00₹515.00n/a11
Jan ’25₹818.35
₹823.73
+0.7%
18.6%₹1,125.00₹515.00n/a11
Dec ’24₹785.40
₹812.25
+3.4%
18.7%₹1,125.00₹515.00₹1,375.5012
Nov ’24₹741.55
₹831.67
+12.2%
20.6%₹1,125.00₹480.00₹1,426.9012
Oct ’24₹873.05
₹809.17
-7.3%
21.9%₹1,125.00₹480.00₹1,400.3012
Sep ’24₹902.60
₹790.38
-12.4%
23.0%₹1,125.00₹480.00₹1,537.5513
Aug ’24₹824.75
₹670.08
-18.8%
15.6%₹900.00₹480.00₹1,362.0013
Jul ’24₹693.20
₹658.54
-5.0%
12.9%₹750.00₹480.00₹1,198.9513
Jun ’24₹622.95
₹658.54
+5.7%
12.9%₹750.00₹480.00₹997.6513
May ’24₹574.95
₹643.77
+12.0%
15.4%₹816.00₹450.00₹1,018.1513
Apr ’24₹563.35
₹640.69
+13.7%
15.7%₹816.00₹450.00₹973.7013
Mar ’24₹538.70
₹640.69
+18.9%
15.7%₹816.00₹450.00₹982.7513
Feb ’24₹529.20
₹679.92
+28.5%
12.4%₹816.00₹460.00₹869.3012
Jan ’24₹561.65
₹679.92
+21.1%
12.4%₹816.00₹460.00₹818.3512
Dec ’23₹576.95
₹709.08
+22.9%
19.0%₹1,060.00₹460.00₹785.4012

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 20:05
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NATCO Pharma Limited is covered by 26 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Sriraam RathiAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited